Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Van Voorhees AS, et al. Among authors: harrold lr. J Dermatolog Treat. 2021 May;32(3):302-309. doi: 10.1080/09546634.2019.1656797. Epub 2019 Oct 3. J Dermatolog Treat. 2021. PMID: 31581919
Reply.
Yun H, Curtis JR, George MD, Greenberg J, Harrold LR. Yun H, et al. Among authors: harrold lr. Arthritis Care Res (Hoboken). 2023 Oct;75(10):2223-2224. doi: 10.1002/acr.25075. Epub 2023 Apr 19. Arthritis Care Res (Hoboken). 2023. PMID: 36530033 No abstract available.
Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.
Harrold LR, Reed GW, Magner R, Shewade A, John A, Greenberg JD, Kremer JM. Harrold LR, et al. Arthritis Res Ther. 2015 Sep 18;17(1):256. doi: 10.1186/s13075-015-0776-1. Arthritis Res Ther. 2015. PMID: 26382589 Free PMC article.
One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.
Harrold LR, Litman HJ, Saunders KC, Dandreo KJ, Gershenson B, Greenberg JD, Low R, Stark J, Suruki R, Jaganathan S, Kremer JM, Yassine M. Harrold LR, et al. Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5. Arthritis Res Ther. 2018. PMID: 29329557 Free PMC article.
142 results